<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p233" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_233{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_233{left:306px;bottom:30px;}
#t3_233{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_233{left:346px;bottom:30px;}
#t5_233{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_233{left:517px;bottom:30px;}
#t7_233{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_233{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_233{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_233{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_233{left:35px;bottom:777px;letter-spacing:0.06px;word-spacing:0.12px;}
#tc_233{left:35px;bottom:759px;letter-spacing:0.05px;word-spacing:0.14px;}
#td_233{left:35px;bottom:739px;letter-spacing:0.03px;word-spacing:0.16px;}
#te_233{left:35px;bottom:720px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tf_233{left:132px;bottom:720px;letter-spacing:0.16px;}
#tg_233{left:493px;bottom:720px;}
#th_233{left:35px;bottom:683px;letter-spacing:0.09px;word-spacing:0.1px;}
#ti_233{left:35px;bottom:665px;letter-spacing:0.09px;word-spacing:0.09px;}
#tj_233{left:35px;bottom:645px;letter-spacing:0.11px;word-spacing:0.08px;}
#tk_233{left:35px;bottom:625px;letter-spacing:0.16px;}
#tl_233{left:405px;bottom:625px;}
#tm_233{left:35px;bottom:589px;letter-spacing:0.08px;word-spacing:0.11px;}
#tn_233{left:35px;bottom:570px;letter-spacing:0.22px;word-spacing:-0.03px;}
#to_233{left:35px;bottom:551px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tp_233{left:132px;bottom:551px;letter-spacing:0.16px;}
#tq_233{left:493px;bottom:551px;}
#tr_233{left:35px;bottom:514px;letter-spacing:0.04px;word-spacing:-0.36px;}
#ts_233{left:35px;bottom:495px;letter-spacing:0.05px;word-spacing:-0.72px;}
#tt_233{left:35px;bottom:476px;letter-spacing:0.02px;word-spacing:0.16px;}
#tu_233{left:35px;bottom:457px;letter-spacing:0.11px;word-spacing:0.08px;}
#tv_233{left:35px;bottom:437px;letter-spacing:0.16px;}
#tw_233{left:396px;bottom:437px;}
#tx_233{left:35px;bottom:401px;letter-spacing:0.07px;word-spacing:0.11px;}
#ty_233{left:35px;bottom:382px;letter-spacing:0.07px;word-spacing:-1.12px;}
#tz_233{left:35px;bottom:363px;letter-spacing:0.03px;word-spacing:0.16px;}
#t10_233{left:35px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t11_233{left:35px;bottom:324px;letter-spacing:0.16px;}
#t12_233{left:405px;bottom:324px;}
#t13_233{left:35px;bottom:288px;letter-spacing:0.04px;word-spacing:0.15px;}
#t14_233{left:35px;bottom:269px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t15_233{left:35px;bottom:249px;letter-spacing:0.09px;word-spacing:0.09px;}
#t16_233{left:35px;bottom:229px;letter-spacing:0.08px;word-spacing:0.1px;}
#t17_233{left:35px;bottom:210px;letter-spacing:0.16px;}
#t18_233{left:405px;bottom:210px;}
#t19_233{left:35px;bottom:174px;letter-spacing:0.06px;word-spacing:-0.18px;}
#t1a_233{left:35px;bottom:155px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1b_233{left:35px;bottom:135px;letter-spacing:0.06px;word-spacing:-0.05px;}
#t1c_233{left:35px;bottom:116px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1d_233{left:35px;bottom:96px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1e_233{left:132px;bottom:96px;letter-spacing:0.16px;}
#t1f_233{left:501px;bottom:96px;}
#t1g_233{left:618px;bottom:777px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1h_233{left:618px;bottom:759px;letter-spacing:0.11px;word-spacing:-0.09px;}
#t1i_233{left:618px;bottom:739px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1j_233{left:618px;bottom:720px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1k_233{left:618px;bottom:700px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1l_233{left:618px;bottom:680px;letter-spacing:0.16px;}
#t1m_233{left:988px;bottom:680px;}
#t1n_233{left:618px;bottom:645px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1o_233{left:618px;bottom:625px;letter-spacing:-0.02px;word-spacing:0.2px;}
#t1p_233{left:618px;bottom:606px;letter-spacing:0.14px;word-spacing:-0.72px;}
#t1q_233{left:618px;bottom:586px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1r_233{left:715px;bottom:586px;letter-spacing:0.16px;}
#t1s_233{left:1084px;bottom:586px;}
#t1t_233{left:618px;bottom:551px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1u_233{left:618px;bottom:531px;letter-spacing:0.17px;word-spacing:-0.33px;}
#t1v_233{left:618px;bottom:512px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1w_233{left:618px;bottom:492px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1x_233{left:618px;bottom:473px;letter-spacing:0.16px;}
#t1y_233{left:988px;bottom:473px;}
#t1z_233{left:618px;bottom:437px;letter-spacing:0.11px;word-spacing:0.07px;}
#t20_233{left:618px;bottom:418px;letter-spacing:0.04px;word-spacing:0.15px;}
#t21_233{left:618px;bottom:398px;letter-spacing:0.04px;word-spacing:0.15px;}
#t22_233{left:618px;bottom:379px;letter-spacing:0.16px;}
#t23_233{left:988px;bottom:379px;}
#t24_233{left:618px;bottom:343px;letter-spacing:0.06px;word-spacing:0.13px;}
#t25_233{left:618px;bottom:324px;letter-spacing:0.06px;word-spacing:0.13px;}
#t26_233{left:618px;bottom:304px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t27_233{left:618px;bottom:284px;letter-spacing:0.11px;word-spacing:0.08px;}
#t28_233{left:618px;bottom:265px;letter-spacing:0.16px;}
#t29_233{left:988px;bottom:265px;}
#t2a_233{left:618px;bottom:229px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2b_233{left:618px;bottom:210px;letter-spacing:0.03px;word-spacing:0.16px;}
#t2c_233{left:618px;bottom:190px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2d_233{left:618px;bottom:171px;letter-spacing:0.16px;}
#t2e_233{left:988px;bottom:171px;}
#t2f_233{left:618px;bottom:135px;letter-spacing:0.09px;word-spacing:-0.27px;}
#t2g_233{left:618px;bottom:116px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2h_233{left:618px;bottom:96px;letter-spacing:0.03px;word-spacing:-0.37px;}
#t2i_233{left:618px;bottom:78px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2j_233{left:618px;bottom:58px;letter-spacing:0.16px;}
#t2k_233{left:988px;bottom:58px;}
#t2l_233{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_233{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_233{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_233{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_233{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_233{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_233{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_233{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts233" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg233Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg233" style="-webkit-user-select: none;"><object width="1210" height="935" data="233/233.svg" type="image/svg+xml" id="pdf233" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_233" class="t s0_233">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_233" class="t s1_233">© </span>
<span id="t3_233" class="t s0_233">(NCCN </span>
<span id="t4_233" class="t s1_233">© </span>
<span id="t5_233" class="t s0_233">), All rights reserved. NCCN Guidelines </span>
<span id="t6_233" class="t s1_233">® </span>
<span id="t7_233" class="t s0_233">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_233" class="t s2_233">NCCN Guidelines Version 4.2024 </span>
<span id="t9_233" class="t s2_233">Head and Neck Cancers </span>
<span id="ta_233" class="t s3_233">MS-92 </span>
<span id="tb_233" class="t s4_233">437. Masterson L, Moualed D, Masood A, et al. De-escalation treatment </span>
<span id="tc_233" class="t s4_233">protocols for human papillomavirus-associated oropharyngeal squamous </span>
<span id="td_233" class="t s4_233">cell carcinoma. Cochrane Database Syst Rev 2014;2:CD010271. </span>
<span id="te_233" class="t s4_233">Available at: </span><span id="tf_233" class="t s5_233">http://www.ncbi.nlm.nih.gov/pubmed/24532092</span><span id="tg_233" class="t s4_233">. </span>
<span id="th_233" class="t s4_233">438. Kofler B, Laban S, Busch CJ, et al. New treatment strategies for </span>
<span id="ti_233" class="t s4_233">HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol </span>
<span id="tj_233" class="t s4_233">2014;271:1861-1867. Available at: </span>
<span id="tk_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/23934317</span><span id="tl_233" class="t s4_233">. </span>
<span id="tm_233" class="t s4_233">439. Hinni ML, Zarka MA, Hoxworth JM. Margin mapping in transoral </span>
<span id="tn_233" class="t s4_233">surgery for head and neck cancer. Laryngoscope 2013;123:1190-1198. </span>
<span id="to_233" class="t s4_233">Available at: </span><span id="tp_233" class="t s5_233">http://www.ncbi.nlm.nih.gov/pubmed/23382042</span><span id="tq_233" class="t s4_233">. </span>
<span id="tr_233" class="t s4_233">440. Cracchiolo JR, Baxi SS, Morris LG, et al. Increase in primary surgical </span>
<span id="ts_233" class="t s4_233">treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates </span>
<span id="tt_233" class="t s4_233">of adverse pathologic features: National Cancer Data Base. Cancer </span>
<span id="tu_233" class="t s4_233">2016;122:1523-1532. Available at: </span>
<span id="tv_233" class="t s5_233">http://www.ncbi.nlm.nih.gov/pubmed/26970050</span><span id="tw_233" class="t s4_233">. </span>
<span id="tx_233" class="t s4_233">441. Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus </span>
<span id="ty_233" class="t s4_233">transoral robotic surgery and neck dissection for oropharyngeal squamous </span>
<span id="tz_233" class="t s4_233">cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. </span>
<span id="t10_233" class="t s4_233">Lancet Oncol 2019;20:1349-1359. Available at: </span>
<span id="t11_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/31416685</span><span id="t12_233" class="t s4_233">. </span>
<span id="t13_233" class="t s4_233">442. Nichols AC, Theurer J, Prisman E, et al. Randomized trial of </span>
<span id="t14_233" class="t s4_233">radiotherapy versus transoral robotic surgery for oropharyngeal squamous </span>
<span id="t15_233" class="t s4_233">cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol </span>
<span id="t16_233" class="t s4_233">2022;40:866-875. Available at: </span>
<span id="t17_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/34995124</span><span id="t18_233" class="t s4_233">. </span>
<span id="t19_233" class="t s4_233">443. Palma DA, Prisman E, Berthelet E, et al. Assessment of toxic effects </span>
<span id="t1a_233" class="t s4_233">and survival in treatment deescalation with radiotherapy vs transoral </span>
<span id="t1b_233" class="t s4_233">surgery for HPV-associated oropharyngeal squamous cell carcinoma: the </span>
<span id="t1c_233" class="t s4_233">ORATOR2 phase 2 randomized clinical trial. JAMA Oncol 2022;8:1-7. </span>
<span id="t1d_233" class="t s4_233">Available at: </span><span id="t1e_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/35482348</span><span id="t1f_233" class="t s4_233">. </span>
<span id="t1g_233" class="t s4_233">444. Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction </span>
<span id="t1h_233" class="t s4_233">chemotherapy followed by reduced-dose radiation and weekly cetuximab </span>
<span id="t1i_233" class="t s4_233">in patients with HPV-associated resectable squamous cell carcinoma of </span>
<span id="t1j_233" class="t s4_233">the oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol </span>
<span id="t1k_233" class="t s4_233">2017;35:490-497. Available at: </span>
<span id="t1l_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/28029303</span><span id="t1m_233" class="t s4_233">. </span>
<span id="t1n_233" class="t s4_233">445. Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for </span>
<span id="t1o_233" class="t s4_233">human papillomavirus-associated squamous-cell carcinoma of the </span>
<span id="t1p_233" class="t s4_233">oropharynx: a single-arm, phase 2 study. Lancet Oncol 2017;18:803-811. </span>
<span id="t1q_233" class="t s4_233">Available at: </span><span id="t1r_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/28434660</span><span id="t1s_233" class="t s4_233">. </span>
<span id="t1t_233" class="t s4_233">446. Chera BS, Amdur RJ, Tepper JE, et al. Mature results of a </span>
<span id="t1u_233" class="t s4_233">prospective study of deintensified chemoradiotherapy for low-risk human </span>
<span id="t1v_233" class="t s4_233">papillomavirus-associated oropharyngeal squamous cell carcinoma. </span>
<span id="t1w_233" class="t s4_233">Cancer 2018;124:2347-2354. Available at: </span>
<span id="t1x_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/29579339</span><span id="t1y_233" class="t s4_233">. </span>
<span id="t1z_233" class="t s4_233">447. Chera BS, Amdur RJ, Green R, et al. Phase II trial of de-intensified </span>
<span id="t20_233" class="t s4_233">chemoradiotherapy for human papillomavirus-associated oropharyngeal </span>
<span id="t21_233" class="t s4_233">squamous cell carcinoma. J Clin Oncol 2019;37:2661-2669. Available at: </span>
<span id="t22_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/31411949</span><span id="t23_233" class="t s4_233">. </span>
<span id="t24_233" class="t s4_233">448. Ma DJ, Price KA, Moore EJ, et al. Phase II evaluation of aggressive </span>
<span id="t25_233" class="t s4_233">dose de-escalation for adjuvant chemoradiotherapy in human </span>
<span id="t26_233" class="t s4_233">papillomavirus-associated oropharynx squamous cell carcinoma. J Clin </span>
<span id="t27_233" class="t s4_233">Oncol 2019;37:1909-1918. Available at: </span>
<span id="t28_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/31163012</span><span id="t29_233" class="t s4_233">. </span>
<span id="t2a_233" class="t s4_233">449. Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-dose </span>
<span id="t2b_233" class="t s4_233">radiation therapy for HPV-associated oropharyngeal carcinoma (NRG </span>
<span id="t2c_233" class="t s4_233">Oncology HN002). J Clin Oncol 2021;39:956-965. Available at: </span>
<span id="t2d_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/33507809</span><span id="t2e_233" class="t s4_233">. </span>
<span id="t2f_233" class="t s4_233">450. Hegde JV, Shaverdian N, Daly ME, et al. Patient-reported quality-of- </span>
<span id="t2g_233" class="t s4_233">life outcomes after de-escalated chemoradiation for human </span>
<span id="t2h_233" class="t s4_233">papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 </span>
<span id="t2i_233" class="t s4_233">trial. Cancer 2018;124:521-529. Available at: </span>
<span id="t2j_233" class="t s5_233">https://www.ncbi.nlm.nih.gov/pubmed/29044458</span><span id="t2k_233" class="t s4_233">. </span>
<span id="t2l_233" class="t s6_233">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
